ACS Journal Cancer shared a post on X:
“Top advances of the year: Perioperative therapy for lung cancer.
2023 saw multiple positive trials of ICIs incorporated into novel treatment paradigms for early stage NSCLC, including overall survival improvement.”
Read further.
Source: ACS Journal Cancer/X